TY - JOUR
T1 - Fair benefits in developing countries
T2 - Maximin as a good start
AU - Macklin, Ruth
N1 - Funding Information:
In addition to the questions this account leaves unanswered, other concerns remain. Ballantyne notes that commercial sponsors constitute 48% of all research conducted in low-and middle-income countries. What about the other 52%, sponsored by not-for-profit institutions and governments? Are fair benefits to the research population not required when the sponsor is a noncommercial one? The arrangement Ballantyne proposes could lead decision makers in the host countries to seek commercial, for-profit sponsors instead of sponsors like the U.S. National Institutes of Health, the UK Medical Research Council, and other industrialized country sponsors of research, as well as the World Health Organization (WHO) and philanthropic organizations like the Wellcome Trust and the Gates Foundation. There is no way of knowing whether the latter types of sponsors are more scrupulous than industry in conducting prior ethical review of research protocols or designing informed consent documents. But the question that looms is whether Bal-lantyne’s scheme is fair to the research subjects and communities in research sponsored by noncommercial entities, since the communities would lack whatever benefits result from the commercially sponsored research.
PY - 2010/6
Y1 - 2010/6
UR - http://www.scopus.com/inward/record.url?scp=77953420514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953420514&partnerID=8YFLogxK
U2 - 10.1080/15265161.2010.482648
DO - 10.1080/15265161.2010.482648
M3 - Article
C2 - 20526967
AN - SCOPUS:77953420514
SN - 1526-5161
VL - 10
SP - 36
EP - 37
JO - American Journal of Bioethics
JF - American Journal of Bioethics
IS - 6
ER -
